BrightPath Biotherapeutics

BrightPath Biotherapeutics Co., Ltd. is a biopharmaceutical company based in Kurume, Japan, specializing in the development of innovative cancer immunotherapy drugs. The company is advancing its lead candidate, ITK-1, a cancer peptide vaccine currently in Phase III clinical trials for the treatment of prostate cancer. Additionally, BrightPath is developing GRN-1201, which is in Phase II trials for non-small cell lung cancer and Phase I trials for melanoma. The company also has research-stage products, including GRN-1301, a neoantigen targeting drug-resistant tumors in non-small cell lung cancer, and iPS-NKT, a therapy utilizing induced pluripotent stem cell-derived NKT cells. Founded in 2003, BrightPath Biotherapeutics aims to stimulate potent immune responses to tumor-associated antigens through its peptide vaccine technology.